Cited 10 times in
Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 송정식 | - |
dc.contributor.author | 이상원 | - |
dc.contributor.author | 이수곤 | - |
dc.contributor.author | 박용범 | - |
dc.contributor.author | 송영구 | - |
dc.date.accessioned | 2015-01-06T16:34:48Z | - |
dc.date.available | 2015-01-06T16:34:48Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 1076-1608 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/98370 | - |
dc.description.abstract | BACKGROUND: Active tuberculosis (TB) risk increases during anti-tumor necrosis factor (TNF) therapy; therefore, latent TB infection (LTBI) screening is recommended in potential TNF inhibitor users. It is unclear whether anti-TNF therapy increases the risk of active TB infection even after standard LTBI treatment. OBJECTIVE: The objective of this study was to compare the risk of active TB development in LTBI-positive versus LBTI-negative TNF inhibitor users following the current national LTBI treatment guidelines for LTBI. METHODS: We retrospectively studied 949 TNF inhibitor users with immune-mediated inflammatory diseases from 2005 to 2012 at the Yonsei University Health System. We compared the incidence of active TB among LTBI-positive TNF inhibitor users treated according to national guidelines (n = 256) and LTBI-negative TNF inhibitor users (n = 521), using Poisson regression. RESULTS: The active TB incidence was 1107 per 100,000 patient-years in LTBI-positive TNF inhibitor users who received standard LTBI treatment and 490 per 100,000 patient-years in LTBI-negative TNF inhibitor users. Analysis showed that despite this numerical trend active TB risk was not statistically significantly elevated in LTBI-positive versus LTBI-negative TNF inhibitor users (incidence risk ratio, 2.15; P = 0.24; 95% confidence interval, 0.6-7.7). CONCLUSIONS: This study demonstrated no statistically significantly increased risk of active TB in LTBI-positive TNF inhibitor users who received standard LTBI treatment compared with LTBI-negative TNF inhibitor users. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 68~73 | - |
dc.relation.isPartOf | JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antirheumatic Agents/adverse effects* | - |
dc.subject.MESH | Antirheumatic Agents/therapeutic use* | - |
dc.subject.MESH | Antitubercular Agents/therapeutic use* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Incidence | - |
dc.subject.MESH | Latent Tuberculosis/drug therapy* | - |
dc.subject.MESH | Latent Tuberculosis/microbiology | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mycobacterium tuberculosis | - |
dc.subject.MESH | Regression Analysis | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Rheumatic Diseases/drug therapy* | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Tuberculosis/epidemiology* | - |
dc.subject.MESH | Tuberculosis/microbiology | - |
dc.subject.MESH | Tumor Necrosis Factor-alpha/antagonists & inhibitors* | - |
dc.title | Active tuberculosis risk with tumor necrosis factor inhibitors after treating latent tuberculosis. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Minkyung Kwon | - |
dc.contributor.googleauthor | Mindong Sung | - |
dc.contributor.googleauthor | Yong-Jin Kwon | - |
dc.contributor.googleauthor | Young Goo Song | - |
dc.contributor.googleauthor | Sang-Won Lee | - |
dc.contributor.googleauthor | Min-Chan Park | - |
dc.contributor.googleauthor | Yong-Beom Park | - |
dc.contributor.googleauthor | Soo-Kon Lee | - |
dc.contributor.googleauthor | Jason Jungsik Song | - |
dc.identifier.doi | 10.1097/RHU.0000000000000074 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02057 | - |
dc.contributor.localId | A02889 | - |
dc.contributor.localId | A01579 | - |
dc.contributor.localId | A02037 | - |
dc.contributor.localId | A02824 | - |
dc.relation.journalcode | J01215 | - |
dc.identifier.eissn | 1536-7355 | - |
dc.identifier.pmid | 24561408 | - |
dc.identifier.url | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&AN=00124743-201403000-00002&LSLINK=80&D=ovft | - |
dc.contributor.alternativeName | Song, Jung Sik | - |
dc.contributor.alternativeName | Lee, Sang Won | - |
dc.contributor.alternativeName | Lee, Soo Kon | - |
dc.contributor.alternativeName | Park, Yong Beom | - |
dc.contributor.alternativeName | Song, Young Goo | - |
dc.contributor.affiliatedAuthor | Song, Jung Sik | - |
dc.contributor.affiliatedAuthor | Lee, Soo Kon | - |
dc.contributor.affiliatedAuthor | Park, Yong Beom | - |
dc.contributor.affiliatedAuthor | Song, Young Goo | - |
dc.contributor.affiliatedAuthor | Lee, Sang Won | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 20 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 68 | - |
dc.citation.endPage | 73 | - |
dc.identifier.bibliographicCitation | JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, Vol.20(2) : 68-73, 2014 | - |
dc.identifier.rimsid | 56557 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.